-
公开(公告)号：US07416738B2
公开(公告)日：2008-08-26
申请号：US10393871
申请日：2003-03-21
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： A modified release dosage form comprising at least one active ingredient and at least two cores surrounded by a shell is provided. The shell comprises at least one opening and provides for modified release of active ingredient upon contacting of the dosage form with a liquid medium. At least one of the cores is distal from the opening. In a preferred embodiment, the dosage form has a pulsatile release profile.
摘要翻译： 提供包含至少一种活性成分和由壳包围的至少两个核心的改型释放剂型。 壳体包括至少一个开口，并且在剂型与液体介质接触时提供活性成分的释放。 核心中的至少一个远离开口。 在优选的实施方案中，剂型具有脉冲释放特征。
-
公开(公告)号：US07635490B2
公开(公告)日：2009-12-22
申请号：US10393752
申请日：2003-03-21
申请人： David Wynn , Gerard P. McNally , Harry S. Sowden
发明人： David Wynn , Gerard P. McNally , Harry S. Sowden
CPC分类号： A23G3/04 , A23G1/54 , A23G3/0029 , A23G3/368 , A23G3/54 , A23L29/30 , A61J3/005 , A61J3/06 , A61J3/10 , A61K9/0004 , A61K9/0056 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2068 , A61K9/2072 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2873 , A61K9/2886 , A61K9/2893 , A61K9/5084 , B30B11/08 , B30B11/34 , B30B15/302 , Y10T428/1352
摘要： The invention provides a dosage form comprising at least one active ingredient, and first core and second cores surrounded by and separated by a shell. The dosage form provides a delay of at least one hour between the initial release of active ingredient contained in said first core and the initial release of active ingredient contained in said second core after contacting of the dosage form with a liquid medium.
摘要翻译： 本发明提供了包含至少一种活性成分的剂型，以及由壳包围并由壳分离的第一核和第二核。 所述剂型在所述剂型与液体培养基接触之后，在所述第一核心中包含的活性成分的初始释放和所述第二核心中包含的活性成分的初始释放之间提供至少1小时的延迟。
-
公开(公告)号：US20090004248A1
公开(公告)日：2009-01-01
申请号：US12143916
申请日：2008-06-23
申请人： Frank Bunick , Joseph Luber , Stephan G. Wiet , Gerard P. McNally , David Wynn
发明人： Frank Bunick , Joseph Luber , Stephan G. Wiet , Gerard P. McNally , David Wynn
IPC分类号： A61K9/20 , A61K9/28 , A61K31/485
CPC分类号： A61K9/0056 , A61K9/209 , A61K31/485
摘要： The present invention relates to a dosage form including both a disintegrative tablet portion and a hard candy portion, wherein: (i) the disintegrative tablet portion comprises at least one pharmaceutically active agent, and (ii) the hard candy portion covers at least 20% of the surface of the disintegrative tablet portion, and wherein the disintegration time of the hard candy portion is at least ten times longer than the disintegration time of the disintegrative tablet portion.
摘要翻译： 本发明涉及包含崩解片剂部分和硬糖部分的剂型，其中：（i）崩解片剂部分包含至少一种药物活性剂，和（ii）硬糖部分覆盖至少20％ 的崩解片部分的表面，并且其中硬糖部分的崩解时间比崩解片剂部分的崩解时间长至少十倍。
-
公开(公告)号：US5976578A
公开(公告)日：1999-11-02
申请号：US932625
申请日：1997-09-17
申请人： Douglas S. Beyerle , John Case , Gerard P. McNally , Frank Hatch
发明人： Douglas S. Beyerle , John Case , Gerard P. McNally , Frank Hatch
CPC分类号： A61K9/0095 , Y10S514/819
摘要： Liquid antacid compositions containing a tri- or di-ester buffer have a reduced final product pH providing for a more efficacious preservative system and better tasting product without compromising to acid neutralization capacity of the antacid.
摘要翻译： 含有三酯或二酯缓冲液的液体抗酸组合物具有降低的最终产品pH，从而提供更有效的防腐剂体系和更好的品尝产品，而不会影响抗酸剂的酸中和能力。
-
公开(公告)号：US5914135A
公开(公告)日：1999-06-22
申请号：US838239
申请日：1997-04-16
申请人： John J. Dubek , Gerard P. McNally , Bruce P. Smith
发明人： John J. Dubek , Gerard P. McNally , Bruce P. Smith
IPC分类号： A61K9/08 , A61K9/00 , A61K33/06 , A61K33/08 , A61K33/10 , A61K33/12 , A61P1/00 , A61P1/04 , A61P1/14
CPC分类号： A61K9/0095 , A61K33/10 , Y10S514/819 , Y10S514/82 , Y10S514/925 , Y10S514/926 , Y10S514/927
摘要： Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.
摘要翻译： 含有一种或多种pH调节剂以保持pH高于9.0，优选高于9.5的碳酸钙液体抗酸组合物。 所得的抗酸液体具有优异的抗微生物侵袭性和增强的味道特性。
-
公开(公告)号：US5989588A
公开(公告)日：1999-11-23
申请号：US940643
申请日：1997-09-30
申请人： Scott H. Korn , Gerard P. McNally , Joseph R. Luber , Tom S. Ells
发明人： Scott H. Korn , Gerard P. McNally , Joseph R. Luber , Tom S. Ells
CPC分类号： A61K33/10
摘要： A method for preventing heartburn episodes in a patient at risk to development of heartburn, comprising administering to the patient, following the heartburn inducing event but prior to development of heartburn, a composition comprising a pharmaceutically effective amount of an H.sub.2 antagonist and an amount of antacid having between about 15 mEq and 46 mEq acid neutralizing capacity.
摘要翻译： 一种用于预防患有胃灼热风险的患者中的胃灼热发作的方法，包括在胃灼热诱发事件之后但在发烧之前施用包含药学有效量的H 2拮抗剂和一定量抗酸剂的组合物 具有约15mEq和46mEq酸中和能力。
-
7.发明授权Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders 失效法莫替丁和硫糖铝的稳定组合用于治疗胃肠道疾病
公开(公告)号：US5593696A
公开(公告)日：1997-01-14
申请号：US342775
申请日：1994-11-21
申请人： Gerard P. McNally , Edward J. Roche
发明人： Gerard P. McNally , Edward J. Roche
CPC分类号： A61K9/2081 , A61K31/70 , A61K9/0056
摘要： Oral dosage forms are disclosed which are effective for treating of gastric disorders. The dosage forms contain, as active ingredients, famotidine and sucralfate. In the dosage form, the famotidine is provided with a barrier layer which prevents interaction between the famotidine and the sucralfate, which improves the stability of the dosage form.
摘要翻译： 公开了对治疗胃病有效的口服剂型。 剂型含有法莫替丁和硫糖铝作为活性成分。 在剂型中，法莫替丁具有防止法莫替丁和硫糖铝之间的相互作用的阻隔层，这提高了剂型的稳定性。
-
公开(公告)号：US09668993B2
公开(公告)日：2017-06-06
申请号：US12796889
申请日：2010-06-09
IPC分类号： A61K31/192 , A61K31/00 , A61K33/24 , A61K9/16 , A61K9/50
CPC分类号： A61K31/192 , A61K9/1652 , A61K9/5047 , A61K9/5084 , A61K31/00 , A61K33/24 , A61K2300/00
摘要： A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.
-
公开(公告)号：US5631026A
公开(公告)日：1997-05-20
申请号：US455234
申请日：1995-05-31
CPC分类号： A61K33/10 , A61K33/12 , Y10S514/951 , Y10S514/97
摘要： The present invention relates to an aqueous pharmaceutical suspension for oral use, and a method of preparation, having antacid and antiulcer properties which contains a therapeutically effective amount of calcium carbonate in combination with magnesium carbonate and/or magnesium trisilicate and a carboxylic acid pH adjusting agent.
摘要翻译： 本发明涉及用于口服的水性药用悬浮液和具有抗酸和抗溃疡性质的制备方法，其含有治疗有效量的碳酸钙与碳酸镁和/或三硅酸镁和羧酸pH调节剂的组合 。
-
公开(公告)号：US5455050A
公开(公告)日：1995-10-03
申请号：US153005
申请日：1993-11-12
CPC分类号： A61K33/10 , A61K33/12 , Y10S514/951 , Y10S514/97
摘要： The present invention relates to an aqueous pharmaceutical suspension for oral use, and a method of preparation, having antacid and antiulcer properties which contains a therapeutically effective amount of calcium carbonate in combination with magnesium carbonate and/or magnesium trisilicate and a carboxylic acid pH adjusting agent.
摘要翻译： 本发明涉及用于口服的水性药用悬浮液和具有抗酸和抗溃疡性质的制备方法，其含有治疗有效量的碳酸钙与碳酸镁和/或三硅酸镁和羧酸pH调节剂的组合 。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.022 秒)
